文献速递眼整形与眼眶

血清生物标志物与Graves眼病疾病活动度、严重程度及甲泼尼龙反应相关:一项蛋白质组学研究

Serum Biomarkers Linked to Disease Activity, Severity, and Methylprednisolone Response in Graves' Orbitopathy: A Proteomic Study.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2025-01-01

该研究对111例Graves眼病(GO)、16例特发性眼眶炎症(IOI)、10例IgG4相关眼眶病(IgG4-ROD)及25例健康对照的血清进行368种炎症蛋白的蛋白质组学检测,未发现与GO活动度或严重程度相关的差异表达蛋白,但发现IVMP无应答者血清VEGF-A显著升高,VEGF-A预测IVMP应答的AUC为77.3%,联合TSI可提高预测准确性。

要点

  • 未发现与GO活动度或严重程度相关的差异表达蛋白。
  • IVMP无应答者血清VEGF-A显著高于应答者,VEGF-A预测应答AUC为77.3%。
  • VEGF-A联合TSI预测标准IVMP治疗的中重度GO应答AUC达84%。

核心结论

  • 血清VEGF-A在IVMP无应答者中升高,可能作为预测GO治疗反应的生物标志物。
  • GO与IOI及IgG4-ROD共享免疫病理生物学特征。

研究设计与样本

  • 研究纳入GO患者111例、IOI患者16例、IgG4-ROD患者10例及健康对照25例,采用Olink Explore Inflammation panel靶向检测368种炎症蛋白。
  • GO活动度、严重程度及IVMP反应通过回顾性评估,差异表达蛋白定义为Log2-fold change <-0.5或>0.5且FDR校正P < 0.05。

主要发现

  • 未发现与GO活动度或严重程度相关的差异表达蛋白。
  • FDR校正后未发现与IVMP反应相关的差异表达蛋白,样本量有限(应答者22例 vs 非应答者16例)。
  • FDR校正前与IVMP反应相关的五个排名靠前蛋白经Luminex或ELISA验证,显示IVMP无应答者VEGF-A显著升高。
  • VEGF-A预测治疗反应的AUC为77.3%(敏感性=77.3%,特异性=75%)。
  • VEGF-A联合甲状腺刺激免疫球蛋白(TSI)提高预测准确性,尤其在接受标准IVMP治疗的中重度疾病患者中(AUC 84%,敏感性91.7%,特异性75%)。

关键数值与推荐

  • 差异表达蛋白定义为Log2-fold change <-0.5或>0.5且FDR校正P < 0.05。
  • VEGF-A预测IVMP应答的AUC为77.3%(敏感性=77.3%,特异性=75%)。
  • VEGF-A联合TSI预测标准IVMP治疗的中重度GO应答的AUC为84%(敏感性91.7%,特异性75%)。

临床怎么用

  • 血清VEGF-A可能有助于预测GO患者对IVMP的治疗反应,联合TSI可提高预测准确性。
  • GO与IOI及IgG4-ROD存在共享的免疫病理特征,提示跨疾病生物标志物研究的潜在价值。

局限性

  • IVMP反应分析样本量有限(应答者22例 vs 非应答者16例),可能导致FDR校正后未检出显著差异。
  • 研究为回顾性评估GO活动度、严重程度及IVMP反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify biomarkers related to disease activity, severity and response to intravenous methylprednisolone (IVMP) in Graves' orbitopathy (GO), and to evaluate differences in serum proteome between GO, IgG4-related orbital disease (IgG4-ROD) and idiopathic orbital inflammation (IOI). METHODS: Serum proteomics targeting 368 inflammatory proteins (Olink Explore Inflammation panel) was performed on biobank samples from patients with GO (n = 111), IOI (n = 16), IgG4-ROD (n = 10), and healthy controls (n = 25). GO activity, severity and response to IVMP were assessed retrospectively. Differentially expressed proteins (DEPs) were defined as Log2-fold change <-0.5 or >0.5 and false discovery rate (FDR)-adjusted P < 0.05. RESULTS: No DEPs were associated with GO activity or severity. No DEPs linked to IVMP response were seen after FDR correction, likely because of limited sample size (22 responders vs. 16 non-responders). However, five top-ranked proteins related to IVMP response prior to FDR correction were further evaluated by Luminex or ELISA, showing significantly higher VEGF-A in IVMP non-responders. Receiver operator characteristic analysis showed that VEGF-A predicted treatment response with an area under the curve (AUC) of 77.3% (sensitivity = 77.3%, specificity = 75%). Combining VEGF-A and thyroid stimulating immunoglobulins improved predictive accuracy, especially in patients receiving standard IVMP treatment for moderate-to-severe disease (AUC 84%, sensitivity 91.7%, specificity 75%). Compared to healthy controls, 105 DEPs were found in GO, 83 in IOI and 57 in IgG4-ROD. Forty-eight DEPs were differentially expressed across all three conditions. CONCLUSIONS: Serum VEGF-A is increased in IVMP non-responders and thus may be a biomarker for predicting treatment response in GO. Furthermore, GO shares immunopathobiological features with IOI and IgG4-ROD.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Hötte GJ, Kolijn PM, de Bie M, et al. Serum Biomarkers Linked to Disease Activity, Severity, and Methylprednisolone Response in Graves' Orbitopathy: A Proteomic Study. Invest Ophthalmol Vis Sci. 2025. PMID: 41235865. doi:10.1167/iovs.66.14.32

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。